Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Meindert Boysen

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Pharmacoeconomics|February 5, 2020
Reflections on NICE's Uptake of New Methods: Past, Present, and the 2020 ReviewMeindert Boysen, Ian Watson
BMJ (Clinical Research Ed.)|January 6, 2021
NICE's approach to measuring valueFelix Greaves, Meindert Boysen
The Lancet. Oncology|January 1, 2009
Erlotinib for the treatment of non-small-cell lung cancerMeindert Boysen, Carole Longson, Andrew Stevens
International Journal of Technology Assessment in Health Care|January 8, 2026
Advancing the Use of Artificial Intelligence in Health Technology Assessment Activities: Insights and Next Steps from the 2025 HTAi Global Policy ForumRebecca Trowman, Meindert Boysen, Antonio Migliore, et al.
The Lancet. Oncology|July 9, 2009
Lenalidomide for the treatment of relapsed multiple myelomaElangovan Gajraj, Helen Chung, Meindert Boysen, et al.
BMJ (Clinical Research Ed.)|October 28, 2016
Cancer Drugs Fund: the bigger pictureCarole M Longson, Linda J Landells, Elisabeth George, et al.
International Journal of Health Policy and Management|July 3, 2020
Around the Tables - Contextual Factors in Healthcare Coverage Decisions Across Western EuropeTineke Kleinhout-Vliek, Antoinette de Bont, Meindert Boysen, et al.
BMJ (Clinical Research Ed.)|January 4, 2020
How should we assess the clinical and cost effectiveness of histology independent cancer drugs?Sophie Cooper, Jacoline C Bouvy, Lawrence Baker, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 30, 2016
Multiple Criteria Decision Analysis for Health Care Decision Making--Emerging Good Practices: Report 2 of the ISPOR MCDA Emerging Good Practices Task ForceKevin Marsh, Maarten IJzerman, Praveen Thokala, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 23, 2016
Multiple Criteria Decision Analysis for Health Care Decision Making--An Introduction: Report 1 of the ISPOR MCDA Emerging Good Practices Task ForcePraveen Thokala, Nancy Devlin, Kevin Marsh, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Pharmacoeconomics|February 5, 2020
Reflections on NICE's Uptake of New Methods: Past, Present, and the 2020 ReviewMeindert Boysen, Ian Watson
BMJ (Clinical Research Ed.)|January 6, 2021
NICE's approach to measuring valueFelix Greaves, Meindert Boysen
The Lancet. Oncology|January 1, 2009
Erlotinib for the treatment of non-small-cell lung cancerMeindert Boysen, Carole Longson, Andrew Stevens
International Journal of Technology Assessment in Health Care|January 8, 2026
Advancing the Use of Artificial Intelligence in Health Technology Assessment Activities: Insights and Next Steps from the 2025 HTAi Global Policy ForumRebecca Trowman, Meindert Boysen, Antonio Migliore, et al.
The Lancet. Oncology|July 9, 2009
Lenalidomide for the treatment of relapsed multiple myelomaElangovan Gajraj, Helen Chung, Meindert Boysen, et al.
BMJ (Clinical Research Ed.)|October 28, 2016
Cancer Drugs Fund: the bigger pictureCarole M Longson, Linda J Landells, Elisabeth George, et al.
International Journal of Health Policy and Management|July 3, 2020
Around the Tables - Contextual Factors in Healthcare Coverage Decisions Across Western EuropeTineke Kleinhout-Vliek, Antoinette de Bont, Meindert Boysen, et al.
BMJ (Clinical Research Ed.)|January 4, 2020
How should we assess the clinical and cost effectiveness of histology independent cancer drugs?Sophie Cooper, Jacoline C Bouvy, Lawrence Baker, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 30, 2016
Multiple Criteria Decision Analysis for Health Care Decision Making--Emerging Good Practices: Report 2 of the ISPOR MCDA Emerging Good Practices Task ForceKevin Marsh, Maarten IJzerman, Praveen Thokala, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 23, 2016
Multiple Criteria Decision Analysis for Health Care Decision Making--An Introduction: Report 1 of the ISPOR MCDA Emerging Good Practices Task ForcePraveen Thokala, Nancy Devlin, Kevin Marsh, et al.
Pageof 2